Cytokinetics (NASDAQ:CYTK) Raised to “Overweight” at Morgan Stanley

Cytokinetics (NASDAQ:CYTK – Get Free Report) was upgraded by Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Thursday,Benzinga reports. The brokerage presently has a $67.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $70.00. Morgan Stanley’s price objective points to a […]